<ul data-eligibleForWebStory="false"><li>Anthem Biosciences' $395 million IPO was fully subscribed on day two, receiving bids worth ₹2,638 crore ($307 million) as of 10:24 a.m. IST.</li><li>Shares are expected to begin trading on July 21, with the IPO priced at ₹540-570.</li><li>Anthem Biosciences, a drugmaker established in 2007 with facilities in Bengaluru, specializes in drug discovery, drug efficacy testing, active pharmaceutical ingredients, dietary supplements, and probiotics.</li><li>Indian firms are anticipated to raise $2.4 billion through public issues in July, indicating a potential rebound in primary offerings following earlier disruptions.</li></ul>

Anthem Biosciences' $395 million IPO fully subscribed on day two

Discover more